Heart Disease Trial, Recruiting NCT04927429 Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT04927429
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group A (people with a medical reason for a heart MRI):

  • People aged 18 or older, of any gender, who are willing and able to sign a consent form and take part for the full length of the study
  • People who are already scheduled for a medically necessary heart MRI — for example, due to conditions such as heart failure, chest pain, unexplained breathlessness, valve problems, heart defects, tumours near the heart, aortic disease, exposure to drugs known to affect the heart, or other illnesses that can affect the heart

Group B (healthy volunteers, for testing and building reference data):

  • People aged 18 or older, of any gender, who are willing and able to sign a consent form and take part for the full length of the study

Who may not be able to join:

  • People who cannot safely have an MRI scan due to certain metal implants or devices in their body, such as brain aneurysm clips, nerve stimulators, pacemakers or defibrillators, cochlear (ear) implants, insulin pumps, metal fragments in the eyes, or metal shrapnel or bullets — unless the trial site has assessed those devices as safe for MRI
  • People with severely reduced kidney function (confirm with trial site for exact measurement) who are scheduled to receive a standard MRI contrast dye called GBCA
  • People with a known allergy to GBCA contrast dye, if that dye is part of the planned scan
  • People with a known allergy to ferumoxytol (an alternative contrast agent) or to mannitol (an ingredient in ferumoxytol), if ferumoxytol is part of the planned scan
  • People scheduled for a stress test using the medications adenosine or regadenoson, who have certain heart or lung conditions — including a breathing condition with active wheezing, certain heart rhythm problems without a suitable pacemaker, very low or very high blood pressure, or a known allergy to those medications
  • People who have taken a blood-thinning medication called dipyridamole within the past 48 hours, if a stress test with adenosine or regadenoson is planned
  • People with unstable chest pain, a recent heart attack, or an active heart emergency
  • People with a seizure disorder, if regadenoson is the planned stress medication
  • People who are pregnant
  • Women who are breastfeeding and are scheduled to receive GBCA contrast dye, unless they are willing to discard their breast milk for 24 hours after receiving the dye

Additional exclusions for Group B (healthy volunteers) only:

  • People with a known history of significant illness, including high blood pressure requiring medication, heart attack, diabetes, inherited high cholesterol, heart muscle disease, congenital heart conditions, moderate or severe heart valve disease, stroke, peripheral vascular disease, symptoms of chest pain or breathlessness, or current smoking
  • People who are not able to make their own decisions about participating

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eric E Morgan, M.D., National Heart, Lung, and Blood Institute (NHLBI)

Phone: (240) 408-0498

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 April 2024
Est. completion
31 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To evaluate performance of novel pulse sequences for cardiovascular MRI in patients and healthy volunteers of both genders

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov